MedTrace Logo

The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19

NCT04898985 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-08-17

No results posted yet for this study

Summary

Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study. They will be followed for at least ten years (in the COVID-19 Registry). In addition, 500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).

Conditions

Interventions

DIAGNOSTIC_TEST

ImmunoSEQ

experiment assay

Sponsors & Collaborators

  • Larry Saltzman, MD

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2031-05-20
Completion
2031-05-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04898985 on ClinicalTrials.gov